Long Term Prospective Study of Tai Chi Intervention to Delay the Progression of Subjective Cognitive Impairment
NCT05485025, Not applicable, Unknown, Ruijin Hospital
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Long Term Prospective Study of Tai Chi Intervention to Delay the Progression of Subjective Cognitive Impairment | ClinicalTrials.gov |
| NCT number | NCT05485025 | ClinicalTrials.gov |
| Status | Unknown | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 134 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Ruijin Hospital | ClinicalTrials.gov |
| Conditions | Subjective Cognitive Impairment | ClinicalTrials.gov |
| Interventions | Tai chi training, Group activity | ClinicalTrials.gov |
| First posted | 2022-08-02 | ClinicalTrials.gov |
| Last updated | 2022-08-02 | ClinicalTrials.gov |
Registered outcomes 19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | The global cognitive function of SCI subjects. | 36 months | Repeatable Battery for the Assessment of Neuropsychological Status(RBANS) will be used to assess the global cognitive performance of SCI subjects. | ClinicalTrials.gov |
| Secondary | Memory | 18 months and 36 months | Memory will be assessed using the Auditory verbal learning test-Huashan version (AVLT-H). | ClinicalTrials.gov |
| Secondary | Attention | 18 months and 36 months | Attention will be evaluated by Trial Making Test (TMT). | ClinicalTrials.gov |
| Secondary | Executive function | 18 months and 36 months | Executive function will be evaluated by the Stroop task. | ClinicalTrials.gov |
| Secondary | Language | 18 months and 36 months | Language will be assessed by Boston naming test (30-item version), and Verbal Fluency. | ClinicalTrials.gov |
| Secondary | Working memory test | 18 months and 36 months | Working memory test will be assessed by Number Span Forward and Backward. | ClinicalTrials.gov |
| Secondary | Visual spatial ability | 18 months and 36 months | Visual spatial ability will be assessed by Clock Drawing Test. | ClinicalTrials.gov |
| Secondary | Change from baseline in MoCA score | 18 months and 36 months | Change from baseline in Montreal Cognitive Assessment (MoCA) score. | ClinicalTrials.gov |
| Secondary | Change from baseline in CDR score | 18 months and 36 months | Change from baseline in Clinical Dementia Rating (CDR) Scale score. | ClinicalTrials.gov |
| Secondary | Activities of daily living | 18 months and 36 months | Activities of daily living will be assessed by functional activities questionnaire (FAQ). | ClinicalTrials.gov |
| Secondary | Anxiety | 18 months and 36 months | Anxiety will be assessed by Hamilton Anxiety Rating Scale (HAMA). | ClinicalTrials.gov |
| Secondary | Depression | 18 months and 36 months | Depression will be assessed by Hamilton Depression Rating Scale (HAMD). | ClinicalTrials.gov |
| Secondary | Sleep | 18 months and 36 months | Sleep will be assessed by Pittsburgh Sleep Quality Index (PSQI). | ClinicalTrials.gov |
| Secondary | Brain activity | 36 months | Detecting changes associated with blood flow by fMRI. | ClinicalTrials.gov |
| Secondary | Neurodegeneration in brain structures | 36 months | Brain atrophy will be assessed by Magnetic Resonance Volume Imaging. | ClinicalTrials.gov |
| Secondary | Gut microbiota | 18 months and 36 months | Gut microbiota will be assessed by 16S rRNA sequencing. | ClinicalTrials.gov |
| Secondary | Blood biomarkers | 18 months and 36 months | Inflammatory factors (FGF basic、Eotaxin、G-CSF、GM-CSF、IFN-γ、IL-1β、IL-1ra、IL-2、IL-4、IL-5、IL-6、IL-7、IL-8、IL-9、IL-10、IL-12 (p70)、IL-13、IL-15、IL-17、IP-10、MCP-1 (MCAF)、MIP-1α、MIP-1β、PDGF-BB、RANTES、TNF-α、VEGF) will be measured by Bio-Plex Human Cytokine Assays. Nfl, Aβ40, Aβ42,T-tau, p-tau | ClinicalTrials.gov |
| Secondary | Gait and Hand writing Task | 18 months and 36 months | Using wearable sensors to assess gait and hand writing task. | ClinicalTrials.gov |
| Secondary | Incidence of SCI converted to MCI and Alzheimer's disease. | 36 months | The 3-year incidence of MCI and AD in each group will be compared. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 5
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Clock Drawing Task | Secondary outcome | ConductCognition |
| Picture Naming Test | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Verbal Fluency | Secondary outcome | ConductCognition |
| Verbal Learning | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)